Lydia Michaut is Director of Scientific Governance at Novartis and a molecular immunologist by training. She conducted her Ph.D. with Jules Hoffmann, Nobel Laureate in Physiology or Medicine, in the field of innate immunity. She then worked in Walter Gehring's laboratory at the Biozentrum in Basel, where the homeobox was discovered, a landmark finding in developmental biology.
Her scientific career has since expanded in industry across PK/PD bioanalysis and immunogenicity assessment for biotherapeutics, with a growing focus on the bioanalytical challenges presented by novel therapeutic modalities, specifically oligonucleotides and cell and gene therapies.
She integrates biology and technology through collaborative matrix leadership, connecting multidisciplinary teams and internal and external partners to translate innovation into fit-for-purpose bioanalytical approaches.
This includes team-based applications of multiplex and digital PCR to support target-engagement strategies and mechanistic molecular readouts for novel therapies and New Approach Methodologies (NAMs).
Webinar
Multiplex RT-dPCR for high-sensitivity applications: A use case with Novartis
0Days0Hours0Minutes0Seconds
You will learn
How multiplex RT-dPCR enables applications where sample availability and RNA abundance are limiting
See why multiplex RT-dPCR is suitable for sensitive direct pharmacodynamic readouts
The rationale for selecting the QIAcuity dPCR platform and custom dPCR RNA-Plex Assays
See how scientific exchange between Novartis laboratory teams and QIAGEN supported the development and implementation of the multiplexing approach
How multiplex dPCR can support target-engagement assessment for novel therapies
See how to achieve quantitative measurement of multiple RNA targets while maximizing information from limited biological material.
Data from a collaborative multiplex dPCR case study
Hear practical experience and key results generated through teamwork across Novartis laboratories and QIAGEN, with broader relevance to mechanistic readouts and New Approach Methodologies (NAMs).
About this webinar
Sensitive mRNA analysis is increasingly important for applications where biological samples are limited and molecular targets are present at low abundance, for example, for obtaining sensitive pharmacodynamic readouts. This webinar will present a successful custom multiplex RT-dPCR approach developed by Novartis laboratory teams in close collaboration with QIAGEN.
It will provide a high-level overview of the biological background and research needs, explain the rationale for selecting the QIAcuity dPCR platform and custom dPCR RNA-Plex Assays and share key results and practical experience from their implementation.
The presentation will illustrate how collaborative assay development and multiplexing can maximize molecular information from limited sample material and support target-engagement assessments for novel therapies.
Practical considerations for generating robust, interpretable multiplex RNA data will also be discussed, together with the broader relevance of sensitive mechanistic molecular readouts to New Approach Methodologies (NAMs).
It will provide a high-level overview of the biological background and research needs, explain the rationale for selecting the QIAcuity dPCR platform and custom dPCR RNA-Plex Assays and share key results and practical experience from their implementation.
The presentation will illustrate how collaborative assay development and multiplexing can maximize molecular information from limited sample material and support target-engagement assessments for novel therapies.
Practical considerations for generating robust, interpretable multiplex RNA data will also be discussed, together with the broader relevance of sensitive mechanistic molecular readouts to New Approach Methodologies (NAMs).
